US SMid Cap Biotech Analyst Joseph, along with Dr. Joseph Lim, Yale School of Medicine, discuss Akero Therapeutics’ current and emerging treatments for Metabolic dysfunction-associated steatohepatitis (MASH) liver disease on an Analyst/Industry conference call to be held on March 12 at 10 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKRO:
- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- 89bio price target raised to $37 from $29 at Evercore ISI
- Biotech Alert: Searches spiking for these stocks today
- Akero Therapeutics Announces Pricing of Public Offering of Common Stock